BeOne Medicines Ltd. (ONC)
377.63
-4.64
(-1.21%)
USD |
NASDAQ |
Oct 23, 16:00
378.03
+0.40
(+0.11%)
After-Hours: 20:00
BeOne Medicines Enterprise Value : 36.13B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 36.13B |
| October 22, 2026 | 36.61B |
| October 21, 2026 | 37.05B |
| October 20, 2026 | 36.84B |
| October 19, 2026 | 35.35B |
| October 16, 2026 | 35.24B |
| October 15, 2026 | 35.76B |
| October 14, 2026 | 33.40B |
| October 13, 2026 | 33.15B |
| October 12, 2026 | 33.29B |
| October 09, 2026 | 33.72B |
| October 08, 2026 | 33.26B |
| October 07, 2026 | 34.71B |
| October 06, 2026 | 34.58B |
| October 05, 2026 | 34.46B |
| October 02, 2026 | 34.09B |
| October 01, 2026 | 34.16B |
| September 30, 2026 | 34.91B |
| September 29, 2026 | 34.84B |
| September 28, 2026 | 35.02B |
| September 25, 2026 | 34.38B |
| September 24, 2026 | 34.29B |
| September 23, 2026 | 34.81B |
| September 22, 2026 | 35.13B |
| September 21, 2026 | 34.88B |
| Date | Value |
|---|---|
| September 18, 2026 | 33.34B |
| September 17, 2026 | 33.61B |
| September 16, 2026 | 33.05B |
| September 15, 2026 | 32.89B |
| September 14, 2026 | 33.65B |
| September 11, 2026 | 32.89B |
| September 10, 2026 | 32.40B |
| September 09, 2026 | 33.35B |
| September 08, 2026 | 33.40B |
| September 04, 2026 | 34.11B |
| September 03, 2026 | 34.57B |
| September 02, 2026 | 34.48B |
| September 01, 2026 | 34.15B |
| August 31, 2026 | 34.25B |
| August 28, 2026 | 34.99B |
| August 27, 2026 | 35.59B |
| August 26, 2026 | 35.94B |
| August 25, 2026 | 36.00B |
| August 24, 2026 | 35.54B |
| August 21, 2026 | 35.80B |
| August 20, 2026 | 35.25B |
| August 19, 2026 | 36.05B |
| August 18, 2026 | 35.25B |
| August 17, 2026 | 34.55B |
| August 14, 2026 | 32.99B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | 132.13M |
| CRISPR Therapeutics AG | 3.193B |
| Idorsia Ltd. | 2.970B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 237.40M |
| Revenue (Quarterly) | 1.708B |
| Total Expenses (Quarterly) | 1.470B |
| EPS Diluted (Quarterly) | 2.050 |
| Gross Profit Margin (Quarterly) | 87.80% |
| Profit Margin (Quarterly) | 13.90% |
| Earnings Yield | 1.51% |
| Operating Earnings Yield | 2.12% |
| Normalized Earnings Yield | 1.586 |